PRL and growth hormone-producing pituitary gland neoplasm: Thus, based on this study, dopastatins were developed (BIM-23A387 and BIM-23A760), showing a reduced GH and PRL secretion in the primary cultures of somatotropinomas, especially in the tumors with a partial response to octreotide and lanreotide [158,159].